The role of nitric oxide in renovascular hypertension: from the pathophysiology to the treatment

Naunyn Schmiedebergs Arch Pharmacol. 2022 Feb;395(2):121-131. doi: 10.1007/s00210-021-02186-z. Epub 2022 Jan 7.

Abstract

Renovascular hypertension is one of the most relevant causes of secondary hypertension, mostly caused by atherosclerotic renovascular stenosis or fibromuscular dysplasia. The increase in angiotensin II production, oxidative stress, and formation of peroxynitrite promotes the decrease in nitric oxide (NO) availability and the development of hypertension, renal and endothelial dysfunction, and cardiac and vascular remodeling. The NO produced by nitric oxide synthases (NOS) acts as a vasodilator; however, endothelial NOS uncoupling (eNOS) also contributes to NO reduced availability in renovascular hypertension. NO donors and NO-derived metabolites have been investigated in experimental renovascular hypertension and have shown promissory effects in attenuating blood pressure and organ damage in this condition. Therefore, understanding the role of decreased NO in the pathophysiology of renovascular hypertension promotes the study and development of NO donors and molecules that can be converted into NO (such as nitrate and nitrite), contributing for the treatment of this condition in the future.

Keywords: NO donors; Nitric oxide; Renin-angiotensin system; Renovascular hypertension.

Publication types

  • Review

MeSH terms

  • Angiotensin II / metabolism
  • Animals
  • Blood Pressure
  • Humans
  • Hypertension, Renovascular / drug therapy
  • Hypertension, Renovascular / physiopathology*
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / pharmacology*
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress / physiology

Substances

  • Nitric Oxide Donors
  • Angiotensin II
  • Nitric Oxide
  • NOS3 protein, human
  • Nitric Oxide Synthase Type III